Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Real-world study of Trulicity shows improved adherence and persistence in type 2 diabetes.- Eli Lilly

Written by | 14 Jun 2020 | All Medical News

New real-world data showed Trulicity (dulaglutide), from Eli Lilly, had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment. The real-world study comparing adherence and persistence used U.S. claims data of people with type 2 diabetes initiating weekly injectable treatment with Trulicity, semaglutide or exenatide. Matched cohorts were well balanced for characteristics such as age, gender, adapted Diabetes Complications Severity Index (aDCSI) score and select comorbidities.

At six months, people taking Trulicity showed higher adherence and persistence than those taking semaglutide or exenatide. Further, significantly fewer people discontinued treatment with Trulicity compared to semaglutide or exenatide. In the study of Trulicity versus injectable semaglutide, adherence figures were 59.7 percent (Trulicity) versus 42.7 percent (semaglutide). For persistence: 143.6 days (Trulicity) versus 129.9 days (semaglutide) and for treatment discontinuation: 30.8 percent (Trulicity) versus 40.8 percent (semaglutide).

Finally, in the study of Trulicity versus exenatide, the figures for adherence were: 58.1 percent (Trulicity) versus 40.3 percent (exenatide) and for persistence: 142 days (Trulicity) versus 121.4 days (exenatide). Finally the rate of treatment discontinuation was 32.1 percent (Trulicity) versus 49.4 percent (exenatide). The data were presented during the American Diabetes Association’s (ADA) 80th Scientific Sessions.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.